Menu Search
Equities

4Basebio PLC

4BB:LSE

4Basebio PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1,275.00
  • Today's Change0.00 / 0.00%
  • Shares traded511.00
  • 1 Year change+155.00%
  • Beta1.8498
Data delayed at least 20 minutes, as of Nov 08 2024 16:23 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year 4Basebio PLC had net income fall 48.83% from a loss of 5.15m to a larger loss of 7.67m despite a 88.81% increase in revenues from 268.00k to 506.00k.
Gross margin69.63%
Net profit margin-1,650.67%
Operating margin-1,692.45%
Return on assets-83.78%
Return on equity--
Return on investment-97.43%
More ▼

Cash flow in GBPView more

In 2023, cash reserves at 4Basebio PLC fell by 1.28m. Cash Flow from Financing totalled 6.43m or 1,269.76% of revenues. In addition the company used 6.18m for operations while cash used for investing totalled 1.49m.
Cash flow per share-0.7149
Price/Cash flow per share--
Book value per share-0.4075
Tangible book value per share-0.6396
More ▼

Balance sheet in GBPView more

4Basebio PLC has a Debt to Total Capital ratio of 150.78%, a lower figure than the previous year's 192.05%.
Current ratio2.73
Quick ratio2.53
Total debt/total equity--
Total debt/total capital1.51
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.